CD 134作為一個(gè)重要的免疫檢查點(diǎn)發(fā)揮作用,其在鼠模型中的消耗表明缺乏CD 134表達(dá)導(dǎo)致CD 4+和CD 8 + T細(xì)胞減少。當(dāng)CD 134被其相應(yīng)的配體(OX-40 L)結(jié)合時(shí),產(chǎn)生最佳的T細(xì)胞應(yīng)答,并且在確定免疫應(yīng)答后剩余的記憶T細(xì)胞的量方面起重要作用。還發(fā)現(xiàn)CD 134在癌發(fā)生中起重要作用,因?yàn)橛冕槍?duì)CD 134的體內(nèi)活化抗體治療增強(qiáng)了腫瘤生長(zhǎng),這表明CD 134是重要的腫瘤抑制因子,并且其缺失破壞了對(duì)腫瘤的免疫應(yīng)答 抗小鼠CD 134(OX-86)體內(nèi)抗體-超低內(nèi)毒素該產(chǎn)品同種型對(duì)照:Rat IgG1 Isotype Control for In Vivo - Low Endotoxin [GL113] (ICH2246) 緩沖液:ICH3001-100ml,nICH3002-100ml,nICH3003-100ml, 濃度:≥ 2.0 mg/ml 純度:>98% by SDS-PAGE and HPLC 內(nèi)毒素:≤ 0.5 EU/mg as determined by the LAL method 制劑:Sterile, preservative-free, solution in PBS. BSA and Azide free.
應(yīng)用類型
Activation, Flow Cytometry, Immunohistochemistry, Western Blotting